Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients
Yıl: 2021 Cilt: 25 Sayı: 2 Sayfa Aralığı: 151 - 157 Metin Dili: İngilizce İndeks Tarihi: 29-11-2021
Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients
Öz: Objective: We aimed to evaluate the pulmonary function tests(PFTs) and serum carboxymethyl-lysine (CML) level and their asso-ciation with the disease activity in patients with acromegaly. Mate- rial and Methods: This cross-sectional study included 65acromegalic patients (F/M:28/37) and 52 controls ( F/M:23/29). PFTs such as spirometry and diffusing capacity of the lungs for carbon mo-noxide (DLCO) were performed to determine the lungs’ ability to exc-hange gases. Serum CML levels were measured with the enzyme-linked immunosorbent assay. Basal and nadir growth hor-mone (GH), hemoglobin A1c (HbA1c), and insulin-like growth factor-1 (IGF-1) were also assessed. Results: Serum CML levels weresignificantly higher in acromegalic patients (208.1±80 ng/mL) than in controls (174.2±11 ng/mL), (p=0.02). The evaluated PFTs were expressed as predicted values [forced expiratory volume in the 1st second % (p=0.01), forced vital capacity % (p=0.007), functional residual capacity % (p=0.03), residual volume % (p=0.03), vital ca-pacity % (p=0.007), total lung capacity % (p=0.01), and DLCO% (p=0.02)] that were found to be elevated in acromegalic patients than in controls. CML levels positively correlated with HbA1c (r=0.53, p=0.02) but did not correlate with basal GH levels (r=0.35, p=0.06). GH and IGF-1 levels positively correlated with lung volume in acro-megalic patients. Conclusion: Serum CML levels increased in acro- megaly patients but had no association with the PFTs results. Increased lung volume was the most prominent lung function altera-tion in acromegalic patients; relevantly, we found elevated GH and IGF-1 levels to be associated with the increased lung volumes. Future studies need to evaluate the association between the advanced glycation end-products and complications of acromega
Anahtar Kelime: Akromegali Hastalarında Solunum Fonksiyonu ve Serum Karboksimetil-Lizin Seviyesinin Değerlendirilmesi
Öz: Amaç: Bu çalışmada akromegali hastalarında solunum fonksiyonları,serum karboksimetil-lizin [carboxymethyl-lysine (CML)] seviyeleri ve hastalık aktiviyeleriyle ilişkilerini değerlendirmeyi amaçladık. Gereç veYöntemler: Bu kesitsel çalışmaya 65 akromegali hastası (K/E: 28/37)ve 52 kontrol (K/E: 23/29) olgusu dâhil edilmistir. Solunum fonksiyon testleri (SFT) spirometri ile gaz değişimi ise karbon monoksit difüzyonkapasitesi [diffusing capacity of the lungs for carbon monoxide (DLCO)] ile değerlendirilmiştir. Serum CML düzeyi enzim bağımlı immünosor- bent ölçüm metoduyla ölçülmüştür. Hemoglobin A1c (HbA1c), insülinbenzeri büyüme faktörü-1 [insulin-like growth factor-1 (IGF-1)], bazal ve nadir büyüme hormonu (BH) düzeyleri ölçülmüştür. Bulgular:Serum CML seviyeleri akromegali hastalarında (208,1±80 ng/mL),kontrol hastalarına göre (174,2±11 ng/mL) belirgin olarak daha yük- sekti (p=0,02). SFT ve DLCO; akromegali hastalarında kontrol grubunagöre anlamlı olarak daha yüksek saptandı [% birinci saniyedeki zorluekspiratuar volüm (p=0,01), % zorlu vital kapasite (p=0,007), % fonk-siyonel rezidüel kapasite (p=0,03), % kalıntı hacim (p=0,03), % vitalkapasite (p=0,007), % total akciğer kapasitesi (p=0,01) ve %DLCO(p=0,02)]. CML düzeyi; HbA1c ile pozitif korelasyon gösterirken, (r=0.53, p=0.02), bazal BH ile korelasyon mevcut değildi (r=0.35,p=0.06). Akromegali hastalarında BH ve IGF-1 düzeyleriyle akciğerkapasitesi arasında pozitif korelasyon mevcuttu. Sonuç: Serum CMLdüzeyleri akromegali hastalarında yükselmiştir, ancak SFT ile arasındabir ilişki gösterilememiştir. Artmış akciğer kapasitesi akromegali hasta- larında en sık görülen solunum fonksiyon değişikliğidir ve artmış BH veIGF-1 düzeyleriyle arasında bir ilişki mevcuttu. İleri glikasyon son ürün- leri ve akromegali komplikasyonları arasındaki ilişkinin gösterilebilmesiiçin daha fazla çalışmaya ihtiyaç vardır.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a ret-
- rospective cohort study. United Kingdom Acrome-
- galy Study Group. J Clin Endocrinol Metab. 1998;
- 83:2730-2734. [Pubmed]
- 2. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J
- Med. 1993;86:293-299. [Pubmed]
- 3. Colao A, Ferone D, Marzullo P, Lombardi G. Syste- mic complications of acromegaly: epidemiology,
- pathogenesis, and management. Endocr Rev. 2004;
- 25:102-52. [Crossref] [Pubmed]
- 4. Anagnostis P, Efstathiadou ZA, Gougoura S, Polyzos SA, Karathanasi E, Dritsa P, Kita M, Koukoulis GN.
- Oxidative stress and reduced antioxidative status,
- along with endothelial dysfunction in acromegaly.
- Horm Metab Res. 2013;45:314-318. [Crossref] [Pubmed]
- 5. Yang P, Feng J, Peng Q, Liu X, Fan Z. Advanced glycation end products: potential mechanism
- and therapeutic target in cardiovascular
- complications under diabetes. Oxid Med Cell Lon-
- gev. 2019;6; 2019:9570616. [Crossref] [Pubmed] [PMC]
- 6. Kruse CPS, Cottrill DA, Kopchick JJ. Could calgranu- lins and advanced glycated end products potentiate
- acromegaly pathophysiology? Growth Horm IGF
- Res. 2019;46-47:1-4. [Crossref] [Pubmed]
- 7. Davidson MB. Effect of growth hormone on car- bohydrate and lipid metabolism. Endocr Rev. 1987;
- 8:115-131. [Crossref] [Pubmed]
- 8. Wanger J, Clausen JL, Coates A, Pedersen OF, Bru- sasco V, Burgos F, Casaburi R, Crapo R, Enright P,
- van der Grinten CPM, Gustafsson P, Hankinson J,
- Jensen R, Johnson D, Maclntyre N, McKay R, Miller
- MR, Navajas D, Pellegrino R, Viegi G. Standardisa-
- tion of the measurement of lung volumes. Eur Res-
- pir J. 2005;26:511-522. [Crossref]
- 9. Cushing H, Davidoff LM. The pathological findings in four autopsied cases of acromegaly with a discus-
- sion of their significance Monograph 22, Rockefeller
- Inst. M. Research; 1927. [Link]
- 10. Brody JS, Fisher AB, Gocmen A, DuBois AB. Acro- megalic pneumonomegaly: lung growth in the adult. J Clin Invest. 1970;49:1051-1060. [Crossref] [Pubmed] [PMC]
- 11. Evans CC, Hipkin LJ, Murray GM. Pulmonary func- tion in acromegaly. Thorax. 1977;32:322-327. [Crossref] [Pubmed] [PMC]
- 12. Trotman-Dickenson B, Weetman AP, Hughes JM. Upper airflow obstruction and pulmonary function
- in acromegaly: relationship to disease activity. Q J
- Med. 1991;79:527-538. [Pubmed]
- 13. Harrison BD, Millhouse KA, Harrington M, Nabarro JD. Lung function in acromegaly. Q J Med. 1978;
- 47:517-532. [Pubmed]
- 14. Siafakas NM, Sigalas J, Filaditaki B, Tsirogiannis K. Small airway function in acromegaly. Bull Eur
- Physiopathol Respir. 1987;23:329-334. [Pubmed]
- 15. Donnelly PM, Grunstein RR, Peat JK, Woolcock AJ, Bye PT. Large lungs and growth hormone: an in-
- creased alveolar number? Eur Respir J. 1995;8:
- 938-947. [Pubmed]
- 16. Luboshitzky R, Barzilai D. Hypoxemia and pulmo- nary function in acromegaly. Am Rev Respir Dis.
- 1980;121:471-475. [Crossref] [Pubmed]
- 17. Iandelli I, Gorini M, Duranti R, Bassi F, Misuri G, Pa- cini F, Rosi E, Scano G. Respiratory muscle function
- and control of breathing in patients with acrome-
- galy. Eur Respir J. 1997;10:977-982. [Crossref] [Pubmed]
- 18. García-Río F, Pino JM, Díez JJ, Ruíz A, Villasante C, Villamor J. Reduction of lung distensibility in acro-
- megaly after suppression of growth hormone hyper-
- secretion. Am J Respir Crit Care Med. 2001;1;
- 164:852-857. [Crossref] [Pubmed]
- 19. Merola B, Longobardi S, Sofia M, Pivonello R, Micco A, Di Rella F, Esposito V, Colao A, Lombardi G. Lung
- volumes and respiratory muscle strength in adult
- patients with childhood- or adult-onset growth hor-
- mone deficiency: effect of 12 months' growth hor-
- mone replacement therapy. Eur J Endocrinol.
- 1996;135:553-558. [Crossref] [Pubmed]
- 20. Gläser S, Friedrich N, Ewert R, Schäper C, Nauck M, Dörr M, Völzke H, Felix SB, Krebs A, Wallaschofski
- H, Koch B. Association between serum insulin-like
- growth factor (IGF) I and IGF binding protein-3 and
- lung function. J Clin Endocrinol Metab. 2009;94(7):
- 2452-2458. [Crossref] [Pubmed]
| APA | YALI A, Yaşar M, uygur M, KARAKURT S, GOGAS YAVUZ D (2021). Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients. , 151 - 157. |
| Chicago | YALI A. Serap,Yaşar Mehmet,uygur Meliha melin,KARAKURT SAİT,GOGAS YAVUZ Dilek Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients. (2021): 151 - 157. |
| MLA | YALI A. Serap,Yaşar Mehmet,uygur Meliha melin,KARAKURT SAİT,GOGAS YAVUZ Dilek Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients. , 2021, ss.151 - 157. |
| AMA | YALI A,Yaşar M,uygur M,KARAKURT S,GOGAS YAVUZ D Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients. . 2021; 151 - 157. |
| Vancouver | YALI A,Yaşar M,uygur M,KARAKURT S,GOGAS YAVUZ D Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients. . 2021; 151 - 157. |
| IEEE | YALI A,Yaşar M,uygur M,KARAKURT S,GOGAS YAVUZ D "Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients." , ss.151 - 157, 2021. |
| ISNAD | YALI, A. Serap vd. "Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients". (2021), 151-157. |
| APA | YALI A, Yaşar M, uygur M, KARAKURT S, GOGAS YAVUZ D (2021). Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients. Turkish Journal of Endocrinology and Metabolism, 25(2), 151 - 157. |
| Chicago | YALI A. Serap,Yaşar Mehmet,uygur Meliha melin,KARAKURT SAİT,GOGAS YAVUZ Dilek Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients. Turkish Journal of Endocrinology and Metabolism 25, no.2 (2021): 151 - 157. |
| MLA | YALI A. Serap,Yaşar Mehmet,uygur Meliha melin,KARAKURT SAİT,GOGAS YAVUZ Dilek Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients. Turkish Journal of Endocrinology and Metabolism, vol.25, no.2, 2021, ss.151 - 157. |
| AMA | YALI A,Yaşar M,uygur M,KARAKURT S,GOGAS YAVUZ D Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients. Turkish Journal of Endocrinology and Metabolism. 2021; 25(2): 151 - 157. |
| Vancouver | YALI A,Yaşar M,uygur M,KARAKURT S,GOGAS YAVUZ D Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients. Turkish Journal of Endocrinology and Metabolism. 2021; 25(2): 151 - 157. |
| IEEE | YALI A,Yaşar M,uygur M,KARAKURT S,GOGAS YAVUZ D "Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients." Turkish Journal of Endocrinology and Metabolism, 25, ss.151 - 157, 2021. |
| ISNAD | YALI, A. Serap vd. "Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients". Turkish Journal of Endocrinology and Metabolism 25/2 (2021), 151-157. |
